CHEMOTHERAPY, published by KARGER, is a premier academic journal established in 1960, dedicated to disseminating cutting-edge research and advancements in the fields of drug discovery, infectious diseases, oncology, and pharmacology. With an impressive Scopus ranking placing it in the Q2 category for major disciplines such as Drug Discovery and Infectious Diseases, this journal provides an invaluable platform for researchers and professionals aiming to explore new therapeutic approaches and methodologies. Located in the heart of Switzerland, its publications are a key resource for anyone looking to stay informed about the latest developments and trends in the pharmacological sciences. Researchers can benefit from its diverse scope while contributing to a growing body of knowledge that emphasizes the importance of effective chemotherapeutic strategies in modern medicine. Despite not being an Open Access journal, CHEMOTHERAPY remains committed to maintaining a rigorous peer-review process, ensuring the highest quality of published work.

Drug Metabolism and Disposition is a premier journal published by the American Society for Pharmacology and Experimental Therapeutics, focusing on crucial advancements in the fields of pharmaceutical sciences and pharmacology. Since its inception in 1973, this esteemed journal has established itself as a leading platform for innovative research, earning a prestigious Q1 rating in both Pharmaceutical Science and Pharmacology categories as of 2023. With an impressive Scopus ranking of #52 out of 183 in Pharmaceutical Science and #105 out of 313 in Pharmacology, it occupies a vital place in an increasingly competitive academic landscape. Researchers, professionals, and students alike benefit from its rigorous peer-reviewed articles that delve into drug metabolism processes and their physiological implications, making it an indispensable resource for anyone aiming to advance their understanding of drug disposition and efficacy. This crucial journal contributes significantly to the ongoing dialogue in pharmacology and toxicology, providing insights that help shape future therapeutic strategies and regulatory policies.

Microbial Drug Resistance, published by MARY ANN LIEBERT, INC, is a pivotal journal that explores the critical intersection of microbiology and pharmacology with a keen focus on antibiotic resistance and related issues. Since its inception in 1995, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for innovative studies that inform the global response to antimicrobial resistance. With a commendable position in the Category Quartiles, ranked Q2 in Medicine (miscellaneous) and Q2 in Pharmacology for 2023, it caters to a multidisciplinary audience by addressing the implications of microbial resistance within various medical contexts. Although currently non-Open Access, the journal allows subscribers and institutions to access high-quality, peer-reviewed research, directly impacting policy and practice in healthcare settings. Committed to advancing our understanding and combating the challenges posed by resistant microbes, Microbial Drug Resistance remains an essential publication in the fields of microbiology, immunology, and pharmacology.

The Israel Journal of Veterinary Medicine, published by the Israel Veterinary Medical Association, serves as a vital resource for researchers, professionals, and students in the fields of veterinary medicine and animal science. With a commitment to advancing knowledge across diverse veterinary disciplines, this journal plays a crucial role in disseminating significant findings and innovations that influence both local and global veterinary practices. Although it currently holds a Q4 ranking in both the Animal Science and Zoology and Veterinary (miscellaneous) categories, the journal's open access policy, enabling free availability of articles, aspires to increase its accessibility and engagement among the academic community. The journal's convergence of research from 2007 to 2024 showcases its dedication to continuously contributing to the evolving landscape of veterinary science.

Future Medicinal Chemistry is a premier journal dedicated to the rapidly evolving fields of drug discovery, pharmacology, and molecular medicine. Published by Newlands Press Ltd in the United Kingdom, this journal has garnered significant attention within the academic community, evidenced by its 2023 category rankings in Scopus, placing it in the Q2 quartile for Drug Discovery and the Q3 quartiles for both Molecular Medicine and Pharmacology. With an ISSN of 1756-8919 and an E-ISSN of 1756-8927, Future Medicinal Chemistry has been a cornerstone of scholarly discourse since its inception in 2009, continuously contributing to the advancement of knowledge and discussion in medicinal chemistry. The journal is committed to publishing high-quality, peer-reviewed research that addresses the challenges and innovations in drug development and therapeutic strategies, making it an essential resource for researchers, professionals, and students seeking to stay at the forefront of these critical fields. Engage with the latest findings and methodologies that shape the future of medicine by exploring the wealth of information offered within Future Medicinal Chemistry.

ARCHIV DER PHARMAZIE is a prestigious journal published by WILEY-V C H VERLAG GMBH, dedicated to pioneering advances in the fields of Pharmaceutical Science and Drug Discovery. With an impactful history dating back to its inception in 1822, this journal is recognized for its significant contribution to the pharmaceutical sciences, maintaining an impressive Q2 ranking in both the Drug Discovery and Pharmaceutical Science categories as of 2023. The journal’s commitment to excellence is reflected in its Scopus rankings, placing it in the top tiers of relevant fields, ensuring a broad reach and impact among researchers and professionals. Although Open Access options are not available, ARCHIV DER PHARMAZIE continues to be an invaluable resource for scholars seeking to stay abreast of cutting-edge research and developments in pharmacy and related sciences. The journal’s contributions not only serve as crucial benchmarks in research but also enhance the understanding of pharmaceutical innovations, making it essential reading for both seasoned professionals and students alike.

Journal of Parasitology Research, published by HINDAWI LTD, is a pivotal open-access journal that has been disseminating groundbreaking research in the field of parasitology since 2009. With an ISSN of 2090-0023 and an E-ISSN of 2090-0031, this journal strives to provide researchers, professionals, and students with accessible and high-impact studies that advance understanding of parasitic diseases and their epidemiology. The journal currently holds a Q3 ranking in Infectious Diseases and a Q2 ranking in Parasitology, indicating its significant contribution to the academic community. Furthermore, with a Scopus ranking placing it at #39 in Parasitology and #186 in Infectious Diseases, it plays an essential role in shaping research directions in these fields. As an open-access journal, Journal of Parasitology Research enhances the visibility and accessibility of published works, ensuring crucial findings reach a global audience. With a focus on innovative research, the journal welcomes submissions that explore both theoretical frameworks and practical applications in parasitology, making it an invaluable resource for those dedicated to combating parasitic infections.

INVESTIGATIONAL NEW DRUGS is a prestigious journal published by SPRINGER, dedicated to advancing research in the fields of pharmacology and oncology. With its origins dating back to 1983, the journal continues to play a critical role in disseminating groundbreaking studies and innovative methodologies related to drug development and therapeutic strategies. It holds an impressive impact factor among leading academic publications, ranking in the top quartiles (Q1 and Q2) of its respective categories, evidenced by Scopus rankings of #43/272 in Medical Pharmacology and #88/404 in Medical Oncology. While it offers traditional subscription-based access, it remains an essential resource for researchers, professionals, and students eager to stay abreast of significant advancements in drug research. Through rigorous peer review and comprehensive coverage, INVESTIGATIONAL NEW DRUGS aims to foster the development of effective new therapies and enhance our understanding of pharmacological interventions in oncology.

Parasitologists United Journal is a premier academic outlet dedicated to advancing the field of parasitology. Published by the Egyptian Parasitologists United Society (EPU), this journal serves as a critical platform for researchers, professionals, and students alike, allowing them to share innovative findings and developments in the study of parasites and their impacts on human, animal, and environmental health. With an ISSN of 1687-7942 and an E-ISSN of 2090-2646, it aims to promote knowledge dissemination while fostering collaboration across borders. Although currently not an Open Access journal, its commitment to high-quality, peer-reviewed content ensures that the latest research reaches discerning readers. By featuring a diverse array of articles spanning various aspects of parasitology, the journal significantly contributes to the global understanding of parasitic diseases and their management, making it an essential resource for academic and clinical professionals seeking to enhance their expertise in this vital area of health science.

Archives of Pharmacal Research, published by the Pharmaceutical Society of Korea, is a leading journal in the fields of drug discovery, molecular medicine, and organic chemistry. With an illustrious history spanning from 1978 to 2024, this peer-reviewed journal has earned a remarkable reputation, achieving a Q1 category ranking in each of its primary research areas as of 2023. Ranked #9 in Organic Chemistry and #12 in Drug Discovery among their respective fields, Archives of Pharmacal Research showcases cutting-edge research that contributes significantly to scientific advancements. Although it is not an open-access journal, its impactful publications are crucial resources for researchers, professionals, and students navigating the complexities of pharmacological sciences. The journal's continued commitment to disseminating high-quality research underlines its importance in fostering innovation and expanding knowledge within the pharmaceutical landscape.